Meet
Laura Housman

Laura Housman leads Avalere’s Evidence & Strategy practice, applying her background in evidence generation, commercialization, and strategy to a broad range of client projects.

Before joining Avalere, Laura held a variety of leadership positions in industry and academia, including at Novartis where she led a team in access and health outcomes in support of molecular diagnostics and targeted therapies. Additionally, she founded Access Solutions Consulting, has led a national team in access, outcomes, and population health with Exact Sciences, and developed novel risk-sharing arrangements during her tenure at BlueCross BlueShield of Massachusetts.

Laura has a BA in economics, a Master of Public Health, and a Master of Business Administration from Boston University. She is currently a doctoral candidate in the School of Public Health at Boston University.

Authored Content

September 27, 2023 | Videos > Federal and State Policy

Video: Unpacking the Implications of the Negotiated Drug List, Part 2
In Part 2 of our video series on the negotiated drug list, Avalere experts discuss topics including effectiveness measures that will inform CMS’s maximum fair price determinations, evidence generation strategies for manufacturers with products that have been selected for negotiation, or that are eligible for selection in the future, and CMS’s definition of therapeutic alternatives.
September 25, 2023 | Videos > RWE and Patient-Centered Outcomes

Video: Spotlight on Avalere’s Evidence and Strategy Practice
Laura Housman, Avalere’s Evidence and Strategy Practice Director, discusses her past experience, trends in real-world evidence, and the role of data in advocating for the patient voice.
September 7, 2023 | Videos > Drug Pricing

Video: Unpacking the Implications of the Negotiated Drug List, Part 1
Delve into the far-reaching implications of the recently announced negotiated drug list as Avalere experts provide insights and answers to pressing questions surrounding CMS's landmark decision on Part D drug pricing and its impact on manufacturers, patients, and the future healthcare landscape.
July 27, 2023 | Insights & Analysis > Drug Pricing

How Do IRA Policies and the Enhancing Oncology Model Interact?
Manufacturers should adjust commercial and evidence generation strategies in response to the shifted incentives under the IRA and Enhancing Oncology Model.
June 7, 2023 | Insights & Analysis > Drug Pricing

Which Therapeutic Areas Are Likely to Be Affected by IRA Negotiation?
Sponsors with portfolio or pipeline assets within certain therapeutic areas can prepare for the downstream effects of price negotiation on the market.
April 21, 2023 | Insights & Analysis > Quality Improvement

Diabetes Quality Measure Specifications Published by iDQI
New quality measures related to continuous glucose monitoring (CGM) were published in The Science of Diabetes Self-Management and Care by iDQI.
April 18, 2023 | Videos > Federal and State Policy

Video: IRA Impacts on Evidence and Strategy
Ahead of the Asembia and ISPOR 2023 conferences, Avalere experts discuss the increasing importance of value and evidence strategies as part of Inflation Reduction Act (IRA) implementation planning.
April 13, 2023 | Insights & Analysis > Federal and State Policy

How Will the IRA Impact Product Launch Prices?
IRA inflation rebates and drug price negotiation will impact drug launch prices in Medicare, with spillover effects in the Medicaid and commercial markets.
March 30, 2023 | Insights & Analysis > Federal and State Policy

What Evidence Is Needed for Medicare Drug Price Negotiation?
As CMS clarifies evidence requirements for drug price negotiations, manufacturers should prepare their strategies for asset development and on-market products.
March 16, 2023 | Insights & Analysis > Quality Improvement

iDQI Corporate Roundtable Advances Diabetes Care Quality
On March 2, 2023, the Improving Diabetes Quality Initiative (iDQI) hosted a corporate roundtable to discuss the future of diabetes care and technology.
February 16, 2023 | Insights & Analysis > Federal and State Policy

CMMI Drug Pricing Model Concepts
CMMI releases long-awaited response to President Biden’s executive order on drug pricing with a directive for the Centers for Medicare & Medicaid Services (CMS) to develop three models.
July 1, 2021 | Insights & Analysis > Quality Improvement

Addressing the Diagnostic Journey for Rare Disease Patients
Avalere’s white paper draws on recommendations from a multi-stakeholder workshop to look at roadblocks and solutions for scaling sustainable solutions to address the diagnosis of rare disease.